Figure 3.

PGE₂ release by alveolar M∅. For in vitro HK-BCG treatment, normal alveolar (AM) and peritoneal M∅ (PM) as comparison controls were incubated with 20 μg/ml HK-BCG for 24 hours. For in vivo HK-BCG treatment, mice received 0.5 mg intranasal HK-BCG and alveolar M∅ were harvested 24 hours after administration. (A) M∅ suspension (10⁶/ml) was cultured in RPMI 1640 for 2 hours after which PGE₂ was assayed by ELISA. Values are mean ± SD, n = 3. *P < 0.05 compared with control alveolar M∅ (in vitro). **P < 0.0005 compared with control alveolar M∅ (in vitro). (B) Cells were treated with EDAC to cross-link carboxyl groups of PGE₂ to amines in adjacent proteins. After immunofluorescent staining with anti-PGE₂ antibody, cells were examined by confocal microscopy. Results are representative of 10 separate experiments. Bar = 10 μm.